Balazs Halmos
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (88)
Year:
2026
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Year:
2026
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (35)
Alessandro Di Federico
University of Bologna
Yiyu Zou
associate professor
Albert Einstein College of Medicine
Jorge Nieva
Professor of Clinical Medicine
University of Southern California
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Deniz Demircioglu
Assistant Professor
Icahn School of Medicine at Mount Sinai
Jyoti D. Patel
Northwestern University
Jarushka Naidoo
Honorary Senior Lecturer
Royal College of Surgeons in Ireland
Pragnya Das
Cooper University Hospital
Hirva Mamdani
Karmanos Cancer Institute
Stephen Liu
Associate Professor
Georgetown University School of Medicine
Joshua Reuss
Assistant Professor of Medicine
-
Erin Schenk
Assistant Professor
University of Colorado Anschutz Medical Campus
Daniel Starczynowski
Professor
Cincinnati Children's Hospital Medical Center
Seshiru Nakazawa
Gunma University
Haiying Cheng
Associate Professor
Albert Einstein College of Medicine
Toby C. Campbell
University of Wisconsin-Madison
Ari VanderWalde
Global Head of Clinical Trials
-
Lindsay LaFave
Assistant Professor
Albert Einstein College of Medicine
Varun Gupta
Staff Scientist
Albert Einstein College of Medicine
Vineeth Sukrithan
Assistant Professor of Medicine
The Ohio State University Wexner Medical Center
Alexander Drilon
Thomas Jefferson University Hospital
Misty Shields
Assistant Professor
Indiana State University
Simone Sidoli
Associate Professor
Albert Einstein College of Medicine
Aaron Lisberg
University of California, Los Angeles
Aditi Shastri
Albert Einstein College of Medicine
Naoki Furuya
Ohio State University
Ulrich Steidl
Albert Einstein College of Medicine
Barliz Waissengrin
Assistant professor
Cedars-Sinai Medical Center
William Feng
Dana-Farber Cancer Institute
Lyudmila Bazhenova
University of California
Hossein Borghaei
Professor and Chief, Thoracic Oncology
Fox Chase Cancer Center
Nagla Abdel Karim
University of Virginia
Benjamin Solomon
Professor
University of Melbourne
Srinivas Aluri
Research Assistant Professor
Albert Einstein College of Medicine
Dwight H. Owen
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.